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half-cycle correction method provided more accurate results than calculations with-
out any kind of half-cycle correction with the exception of one set of input param-
eters. ConClusions: Based on our model the most accurate method for half-cycle 
correction is Simpson’s method as in most cases it was the closest to real data. It is 
important to note that with a few exceptions even the standard method’s results were 
more accurate than in cases where no half-cycle correction was applied.
PRM77
APPlicAtion of A Model of decision BAsed on fuzzy logic to 
PhARMAcoeconoMics: tReAtMent of cRohn’s diseAse With Antitnf in 
out of lABel use
Alonso Herreros J.M.1, González-Cuello A.2
1HOSPITAL LOS ARCOS MAR MENOR, SAN JAVIER (MURCIA), Spain, 2Murcia University, 
MURCIA, Spain
objeCtives: We present a model decision based on fuzzy logic, and apply to off 
label use of antiTNF in Crohn’s disease (CD) (Infliximab (IFB) 10 mg/kg/8 weeks, 
adalimumab (ADA) 80mg/2 weeks,. Certolizumab (CZB) 200mg/2weeks). The term 
“fuzzy logic” (FL) was introduced in 1965 by LAZadeh. Compared to traditional logic, 
FL variables may have a truth value in degree. FL has been applied to many fields, from 
economic analysis, to artificial intelligence. However it has not been applied so far to 
pharmacoeconomics. Methods: According to a decision analysis model based on FL 
four fuzzy variables that affect the choice of treatment are defined: treatment success 
(expressed as a probability), cost of success, cost of failure (expressed as inverses), 
and other conditions about the cost (negotiation, handling of drugs...). Based on the 
value of these fuzzy variables, three linguistic variables (High, Medium, Low) are 
defined to expressing convenience of choice. The combination of the three possible 
values for each of the variables gives us 81 possible decision rules, so that the (HHHH) 
would be the most favorable option and (LLLL) the more unfavorable. So a new fuzzy 
variable called “ranking” is established for classifying these options with 7 possible 
values (Very-unfavorable, unfavorable, slightly-unfavorable, neutral, slightly-favorable, 
favorable, very-favorable). The value of the fuzzy variables for antiTNF at 52 weeks 
of treatment, were established based recent meta-analysis and reviews. Results: 
The matrices obtained and corresponding decision rules were: for IFB (0.65, 6.3 10-5, 
-1.17 10-4, 0.075) / (MMML); For ADA (0.41, 9.21 10-5, 6.4 10-5, 0.075) / (MMML); for CZB 
(0.52, 1.30 10-4 1.5 10-4 0.075) / (MHHB). Thus the CZB would be the “slightly-favorable” 
option, versus IFB and ADA (unfavorables). ConClusions: It possible to apply meth-
ods of “FL” to pharmacoeconomic studies According to the model, Certolizumab would 
be a most favorable choice in off-label use for CD.
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objeCtives: Since the introduction of the orphan drugs in Europe, it has been sug-
gested that the general method of appraising drugs for reimbursement is not nec-
essarily suitable for orphan drugs. The National Institute for Health and Clinical 
Excellence indicated that several criteria other than cost and efficacy could be 
considered in reimbursement decisions for orphan drugs. The aim of this study 
was to apply a MCDA framework that was proposed by Hughes-Wilson et al (2012) 
to a range of orphan drugs in different diseases to test the correlation between 
drug price and aggregated MCDA scores for each product. Methods: A MCDA 
framework was developed using the nine criteria suggested by Hughes-Wilson 
et al. A supplementary literature review was conducted to identify other attrib-
utes described in the application of MCDA in rare diseases. A numerical scoring 
system on a scale of one to three was developed for each criterion. Correlations 
between the average annual cost of the drugs and aggregate MCDA scores were 
tested and plotted graphically. Different weightings for each of the attributes were 
also tested. A further analysis was conducted to test the impact of including the 
drug cost as an attribute in the aggregate index scores. Results: The literature 
review identified further commonly cited criteria: ‘convenience of administra-
tion’, ‘age of the target population’, ‘quality of life’, and ‘drug innovation’ that 
were added to the aggregate index scores. In the drugs studied, the R2was 0.808 
and 0.704 when costs were included and not included, respectively. The standard 
error of the slope varied from 7711.9 to 11413.3 when costs were included and not 
included, respectively. ConClusions: This quantitative study provided insight 
into using MCDA and its relationship to annual costs. Further work should explore 
the potential for therapy-specific MCDAs and how to inform value-based pricing 
assessment.
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bACkgRound: Modelers and reimbursement decision makers could both profit 
from a more systematic reporting of the efforts to validate health-economic (HE) 
models. objeCtives: Development of a tool to systematically report validation 
efforts of HE decision models and their outcomes. Methods: A gross list of model 
validation techniques was collected using a literature review, including sources 
outside the HE field. A panel then selected the most important items. Based on 
the Delphi method, the panel members could score items in three e-mail rounds. 
Participants were HE modelling experts, covering various nationalities and work 
environments. They could comment on relevance, feasibility and formulation of 
the items and received feedback on comments from others. This resulted in a draft 
tool of selected items, which was tested and improved in two further rounds. In 
population are 18.5% for males and 9.8% for females. ConClusions: Random sam-
pling from patient level data provided the best approximation of actual NHANES 
population predicted CVD rates. The cholesky decomposition approach was slightly 
limited since only continuous variables could be utilized which could explain the 
deviation from the population predicted CVD rates. Independent sampling under-
estimated the mean risk by ~20%, an interesting finding as many individual simula-
tion models created patients with this approach. Researchers should be cautious 
in their use of summary statistics when populating individual simulation models.
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objeCtives: We have developed a model to evaluate type-2 diabetes prevention 
interventions. We aimed to validate this model against external data to test the accu-
racy of model predictions. MethodsAn individual patient simulation was developed 
to predict longitudinal trajectories of HbA1c, 2-hr glucose, FPG, BMI, systolic blood 
pressure, total cholesterol and HDL cholesterol based on statistical analyses of the 
Whitehall II longitudinal cohort. Criteria for diabetes diagnosis were flexibly speci-
fied. Cardiovascular events were estimated from the QRISK2 algorithm. Microvascular 
complications of diabetes were estimated from the UKPDS outcomes model. Several 
validations were performed to compare model outcomes with reported data from 
external sources. We assessed the predicted diabetes incidence using data from the 
EPIC Norfolk cohort. Data from the Health Survey for England (HSE) 2003 cohort was 
simulated for eight years to compare predicted disease incidence and metabolic 
distributions with HSE 2011 data. We compared microvascular, cardiovascular and 
mortality outcomes in a diabetic population with those observed in the UKPDS. We 
assessed the performance of the model in predicting the results of the ADDITION trial 
for diabetes screening. Results: We found that the model overestimated three-year 
incidence of diabetes, particularly in high risk (HbA1c> 6.0) individuals, but underesti-
mated diabetes incidence in medium risk individuals (HbA1c 5.5-5.9) compared with 
the EPIC-Norfolk data. Predictions from HSE 2003 were fairly accurate. Predictions 
for microvascular events were similar to the UKPDS, but cardiovascular disease and 
mortality were slightly under-predicted. The model replicated the non-significant 
difference seen between control and intervention arms of the ADDITION trial, but 
overestimated total mortality and cardiovascular disease. ConClusions: The SPHR 
Diabetes model appears to be fairly accurate at predicting external data, but has 
a tendency to overestimate mortality rates in a newly diagnosed diabetic cohort, 
and underestimate cardiovascular disease and mortality compared with the UKPDS.
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objeCtives: Often in cost-effectiveness analysis (CEA) of oncologic drugs, survival 
data from a randomized controlled trial are extrapolated to a lifetime horizon using 
parametric regression techniques. To capture parameter uncertainty in the analysis, 
regression parameters along with other model parameters are varied in probabilistic 
sensitivity analysis. However, structural uncertainty in the choice of regression 
model is rarely investigated. This study discusses the use of model averaging and 
provides an example to address structural uncertainty in CEA. Methods: Using a 
cohort partition model, the numbers of patients in “progression-free”, “progressed”, 
and “dead” health states were calculated directly from progression-free survival 
(PFS) and overall survival (OS) curves. Weibull, exponential, lognormal, log-logistic, 
generalized gamma, and Gompertz parametric models were used to extrapolated 
these curves to a lifetime horizon. Total costs, life year (LY), and quality adjusted 
life year (QALY) for each regression model were estimated. Weighted results across 
all models were calculated, based on weights that were derived from Akaike’s or 
Bayesian Information Criterion (AIC or BIC) parameters. Results: Evaluating 
solely on BIC values, the lognormal distribution was identified as the best model 
for both survival curves. This resulted in the lowest observed ICERs. When model 
selection was based on considerations involving the log-cumulative hazard plots, 
clinical plausibility, and AIC/ BIC for each distribution, the Weibull distribution was 
selected for both curves, resulting in a 29% and 27% increase in the ICER for QALY 
and LY, respectively. Similar increases were observed when model averaging was 
applied using BIC-derived weights. In this case, model averaging produced results 
that were similar to those where model selection was based on multiple criteria.  
ConClusions: Choice of parametric models often has the biggest impact on the 
outcomes in CEAs in oncology. Model averaging takes into account the structural 
uncertainty surrounding the choice of parametric models.
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objeCtives: To compare three different half-cycle correction methods and their 
effect on the final results of Markov models. Methods: To assess the relative per-
formance of the alternatives to the standard half-cycle correction we constructed a 
5-state Markov model where the courses of the number of patients in health states 
follow different shapes to represent the most likely cases in modelling practise. We 
applied three different correction methods (standard half-cycle correction, Simpson’s 
method and using the mid-cycle values) and we also looked at the results without any 
correction and with different numbers of Markov cycles. We conducted a sensitivity 
analysis by changing the input parameters of our model. In total we examined 80 
cases. Results: In our Markov model Simpson’s method provided the most accurate 
results where the difference from real data was less than 0.1% in 67 of the 80 cases. 
The second most accurate method was using the mid-cycle values. The standard 
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objeCtives: Within health economic models of metastatic cancer therapies assump-
tions on the relationship between progression-free survival (PFS) / time-to-progres-
sion (TTP) and overall survival (OS) are typically required; notably when OS data are 
immature or unavailable. A review was undertaken to identify the methods that have 
been used within health economic models regarding this relationship and to identify 
the rationale given for the approach taken, specifically in those situations where OS 
data were not available or immature. Methods: All NICE technology appraisals in 
the advanced and/or metastatic cancer setting completed by December 2013 were 
reviewed. The review included all relevant appraisal documents publicly available on 
the NICE website containing information on the methods used and/or rationale for 
the approach taken to model the relationship between OS and PFS/TPP within the 
health economic model. This included the sponsor submission and updated analyses, 
the independent Assessment Report, and other reports/analyses in relation to the 
appraisal process. Results: In those instances where OS data were immature or not 
available, PFS/TTP was typically assumed to be a valid surrogate of OS. Justification 
for this assumption was inconsistently reported. In some health economic models 
a quantification of the assumed relationship was informed by published evidence 
and/or expert judgement. In some cases attempts were made to explore the potential 
impact of this relationship in sensitivity analysis. ConClusions: The methods and/
or rationale given for the approach used to model the relationship between OS and 
PFS/TTP in health economic models has been inconsistently reported and justified. 
Whilst some health economic models attempted to quantify this relationship, further 
transparency is required. A consensus needs to emerge on the most appropriate 
approaches to be used within health economic models to quantify this relationship, 
specifically when OS data are not available or immature and to identify the circum-
stances when particular approaches may be most relevant.
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objeCtives: Patient-level utility values for different stages of MBC and toxicities 
commonly associated with chemotherapy regimens are useful for health economic 
assessments. Three methods to estimate utilities exist when direct utility data are 
not available: utility ‘mapping’ from existing disease-specific scales, vignette studies 
that describe the health states; or derivation of preference-based measures from 
an existing condition-specific scale. This study compares utility estimates in MBC 
utilizing the above methods. Methods: Based on data from a phase 3 clinical 
trial in MBC (N= 1102) utility mapping was conducted using a published regression 
algorithm to convert the EORTC QLQ-C30 questionnaire to the EQ-5D utility. Mean 
utility values were estimated for relevant health states: stable disease (SD), tumor 
response (TR), disease progression (DP) and common toxicities. Results were com-
pared to previously published values obtained for a vignette study conducted in 
one hundred members of the general public. Results: Observed MBC utilities were 
similar in mapping vs. vignette studies for SD: 0.697 vs. 0.715, and TR: 0.782 vs. 0.790. 
General public respondents in the vignette study assigned much lower utility to 
symptomatic DP (0.443) vs. imaging-based DP in mapping study (0.679); and disutil-
ity for toxicities: vomiting: 0.103 vs. 0.050; fatigue 0.115 vs. 0.029; febrile neutropenia 
0.150 vs. 0.012 (vignette vs. mapping respectively). Hand-foot syndrome, stomatitis 
and hair loss were not associated with disutility in the mapping study (potentially 
due to small sample size) while disutility of 0.116; 0.151; and 0.114 were reported 
by the vignette study. ConClusions: Utilization of different methods to estimate 
utilities in MBC may lead to a wide range of estimated values with potentially sig-
nificant implications for health economic evaluation. Caution must be exercised 
when comparing utility values derived using different methods. It is preferable to 
collect such data from patients directly and use vignettes as a last resort.
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objeCtives: To compare different COPD cost-effectiveness models with respect 
to structure and input parameters and to cross validate the models by running 
the same hypothetical treatment scenarios. Methods: COPD modeling groups 
simulated four hypothetical interventions with their model and compared the 
results with a reference scenario of no intervention. The four interventions mod-
eled assumed: 1) 20% reduction in decline in lung function, 2) 25% reduction in 
exacerbation frequency, 3) 10% reduction in all-cause mortality and 4) all these 
effects combined. The interventions were simulated for a five-year and lifetime 
horizon with standardization, if possible, for sex, age, COPD severity, smoking status, 
exacerbation frequencies, mortality due to other causes, utilities, costs and dis-
count rates. Furthermore, uncertainty around the outcomes of intervention four was 
compared. Results: Seven out of nine contacted COPD modeling groups agreed to 
participate. Differences in 5-year QALY gains ranged from 0.00020 to 0.039 for inter-
vention one, 0.0089 to 0.075 for intervention two and 0.017 to 0.048 for intervention 
three. The difference in costs ranged from € 561 to € 912 for intervention one, € 739 
to € 1350 for intervention two and € 1140 to € 1618 for intervention three. The 5-year 
cost-effectiveness ratios (ICERs) for the most comprehensive intervention, interven-
tion four, was € 17,000/QALY for two models, € 25,000-€ 28,000/QALY for three models 
addition, the Dutch National Health Care Institute commented on usefulness for 
decision makers, while a separate group of 50 HE experts could comment during a 
workshop at ISPOR Montreal 2014. Results: 35 Validation techniques were identi-
fied and grouped into four categories: conceptual model validation, computerized 
model validation, data validation and operational validation. Around 30 HE experts 
commented in each of the first three Delphi rounds, resulting in a 15 item draft 
tool. The Dutch health care advisory institute suggested to add one more item. 
Participants from the ISPOR workshop delivered 19 filled-in questionnaires. A fourth 
round resulted in 17 responses. This led to a refined version containing 16 items, 
which is currently sent out for a final, fifth round. ConClusions: When filled 
out by the modellers, AdVISHE (Assessment of the ValIdation Status of Health-
Economic decision models) supports model users in assessing the validation status 
of a model It will be useful as part of reimbursement dossiers, by providing system-
atic and transparent insight into the validation efforts performed and their results.
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objeCtives: Traditional indirect treatment comparison methods assume the 
underlying survival profiles of treatments are similar (i.e. proportional hazards). This 
assumption is unlikely to hold for the comparison of ipilimumab and vemurafenib: 
Whereas vemurafenib exhibits improved short-term survival compared with ipili-
mumab, pooled study data for ipilimumab consistently show that patients achieve 
durable long-term survival. We present a method to compare across trials with dif-
fering survival profiles by accounting for follow-on treatments and different patient 
baseline characteristics. Methods: Comparative survival estimates for ipilimumab 
and vemurafenib were produced using patient-level data from trial CA184-024 for 
ipilimumab and published survival curve fits from BRIM-3 (along with registry data) 
for vemurafenib. The BRIM-3 vemurafenib overall survival curve was adjusted to 
account for (a) the effect of second-line ipilimumab (via a tunnel-state methodol-
ogy) and (b) differences in patient baseline characteristics between BRIM-3 and 
CA184-024, by means of a model (Korn model), constructed to predict the outcomes 
for dacarbazine-treated patients. The resulting survival estimates were compared 
with naïve unadjusted survival curve fits, and estimates produced using a hazard 
ratio (from an indirect comparison) to the ipilimumab data. Results: Estimated 
survival for ipilimumab was 3.3 years (mean). Predicted survival for vemurafenib, 
using a naïve comparison, was 3.0 years (mean). Adjusting for second-line ipili-
mumab and different baseline characteristics resulted in an estimate of 2.8 years 
for vemurafenib. When a hazard ratio was applied to the ipilimumab data, which 
underlies the here strong assumption that the vemurafenib overall survival profile 
is similar to that of ipilimumab, predicted survival for vemurafenib increased to 4.2 
years.ConClusions: Depending on the methodology used, the mean predicted 
survival for vemurafenib varied from 2.8 to 4.2 years. Alternative methods that 
incorporate the long-term survival profile of ipilimumab (naïve comparison or more 
sophisticated adjustment methodology) demonstrate a higher number of life years 
with ipilimumab versus vemurafenib. 
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objeCtives: Alzheimer’s Disease destroys brain cells, causing problems with mem-
ory, thinking, and behavior severe enough to affect work, family and social relation-
ships, and, eventually, the most basic activities of daily living. Different treatment 
options have been introduced and evaluated from a health economic perspective. 
However, given the specific characteristics of the disease an evaluation of existing 
models is needed. Methods: The following databases were searched systemati-
cally: PubMed, Health Technology Assessment Database, NHS Economic Evaluation 
Database, Cochrane Central Register of Controlled Trials, Cochrane Database of 
Systematic Reviews, DAHTA-database, PSYNDEX and PsycINFO. For the abstracts 
that met the pre-defined inclusion criteria, full text articles were obtained and 
evaluated for inclusion in the assessment. Results: After eliminating duplicates 
the search indicated yielded 1’219 articles of which another 940 were excluded based 
on the title selection. Finally 59 articles have been reviewed in full text after abstract 
review. Out of those articles 39 were deemed to be relevant based on the research 
question. The majority of models (48%) have been Markov models, other methods 
being used were various statistical analysis applications, micro-simulation, and 
discrete-event simulations. Limitations of existing models include the following: 
Focus on cognitive function as disease progression only; lack of inclusion of correla-
tion between disease progression and other factors (e.g. residential status); lack of 
complete structure of diagnosis and treatment of disease (e.g. including non-drug 
treatments). Based on the Drummond checklist for health economic models the 
quality of models proved generally to be high but the majority of those lack present-
ing a comprehensive pathway of the natural history of the disease. ConClusions: 
Current models do not allow decision makers optimally characterizing the disease, 
to better assess the costs and benefits of a wide range of potential interventions. 
Potential new models need to take the disease characteristics and specifics more 
appropriate into account.
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